L.A. (Lisa) de Jong, MSc

PhD candidate Pharmacoeconomics

E-mail:
l.a.de.jong rug.nl

Research

Postal address:
A Deusinglaan
1
Groningen
Netherlands
Publications
  1. Combinatietherapie heeft een toegevoegde waarde bij vaatziekte: Rivaroxaban en acetylsalicylzuur bij stabiel atherosclerotisch vaatlijden

    Ten Cate, H., Elsman, B., Gilst, van, W., Jong, de, L., van Laarhoven, H., Liem, A. & Warlé, M., 16-Aug-2019, In : Pharmaceutisch Weekblad. 154

    Research output: Contribution to journalArticleAcademicpeer-review

  2. Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings

    de Jong, L. A., Groeneveld, J., Stevanovic, J., Rila, H., Tieleman, R. G., Huisman, M. V., Postma, M. J. & van Hulst, M., 2019, In : PLoS ONE. 14, 9, 17 p., e0222658.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands

    Gout-Zwart, J. J., de Jong, L. A., Saptenno, L. & Postma, M. J., 18-Sep-2019, In : PharmacoEconomics - open. 10 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier

    van der Pol, S., de Jong, L. A., Vemer, P., Jansen, D. E. M. C. & Postma, M., Oct-2019, In : Value in Health. 22, 10, p. 1119-1127 9 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis

    de Jong, L. A., Gout-Zwart, J. J., van den Bosch, M., Koops, M. & Postma, M. J., 3-Apr-2019, In : Journal of Medical Economics. 22, 4, p. 306-318 13 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (7) »

View graph of relations

ID: 54857152